PL2651975T3 - Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania - Google Patents

Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania

Info

Publication number
PL2651975T3
PL2651975T3 PL11848839T PL11848839T PL2651975T3 PL 2651975 T3 PL2651975 T3 PL 2651975T3 PL 11848839 T PL11848839 T PL 11848839T PL 11848839 T PL11848839 T PL 11848839T PL 2651975 T3 PL2651975 T3 PL 2651975T3
Authority
PL
Poland
Prior art keywords
denga
seroty
respectivity
application
monoclonal antibodies
Prior art date
Application number
PL11848839T
Other languages
English (en)
Inventor
Paul Anthony Macary
Ee Ping Evelyn Teoh
Brendon John Hanson
En Wei Teo
Angeline Pei Chiew Lim
Mah Lee Mary Ng
Shee Mei Lok
Petra Eveliina Kukkaro
Original Assignee
Dso Nat Laboratories
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dso Nat Laboratories, Nat Univ Singapore filed Critical Dso Nat Laboratories
Publication of PL2651975T3 publication Critical patent/PL2651975T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11848839T 2010-12-14 2011-12-14 Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania PL2651975T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42308510P 2010-12-14 2010-12-14
EP11848839.4A EP2651975B1 (en) 2010-12-14 2011-12-14 Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
PCT/SG2011/000436 WO2012082073A1 (en) 2010-12-14 2011-12-14 Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof

Publications (1)

Publication Number Publication Date
PL2651975T3 true PL2651975T3 (pl) 2018-04-30

Family

ID=46244986

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11848839T PL2651975T3 (pl) 2010-12-14 2011-12-14 Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania

Country Status (28)

Country Link
US (2) US9376486B2 (pl)
EP (1) EP2651975B1 (pl)
JP (2) JP6483337B2 (pl)
KR (2) KR101904232B1 (pl)
CN (1) CN103534270B (pl)
AU (2) AU2011341744B2 (pl)
BR (1) BR112013015129B1 (pl)
CA (1) CA2821268C (pl)
CO (1) CO6801636A2 (pl)
CY (1) CY1119854T1 (pl)
DK (1) DK2651975T3 (pl)
EA (1) EA201390874A1 (pl)
ES (1) ES2644236T3 (pl)
HR (1) HRP20171580T1 (pl)
HU (1) HUE035609T2 (pl)
IL (1) IL226957B (pl)
LT (1) LT2651975T (pl)
MX (1) MX348152B (pl)
MY (2) MY166537A (pl)
PH (2) PH12013501242B1 (pl)
PL (1) PL2651975T3 (pl)
PT (1) PT2651975T (pl)
RS (1) RS56737B1 (pl)
SG (2) SG191155A1 (pl)
SI (1) SI2651975T1 (pl)
SM (1) SMT201700477T1 (pl)
WO (1) WO2012082073A1 (pl)
ZA (1) ZA201304459B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
ES2644236T3 (es) 2010-12-14 2017-11-28 National University Of Singapore Anticuerpo humano monoclonal con especificidad para el virus Dengue serotipo 1 E proteína y usos de la misma
US9821050B2 (en) 2012-04-02 2017-11-21 The University Of North Carolina At Chapel Hill Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions
WO2014064707A1 (en) * 2012-10-26 2014-05-01 International Centre For Genetic Engineering And Biotechnology Pichia pastoris -expressed dengue virus like particles
KR20160027019A (ko) 2013-06-26 2016-03-09 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 뎅기 바이러스 백신에 대한 방법 및 조성물
CA2938590C (en) 2014-02-11 2023-10-17 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
JP7155009B2 (ja) 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
US10526398B2 (en) * 2018-06-12 2020-01-07 National Defense Medical Center Anti-dengue virus antibodies and applications thereof
US12161890B2 (en) 2018-08-07 2024-12-10 Cz Biohub Sf, Llc Antibodies against dengue virus and related methods
US12600752B2 (en) 2019-11-20 2026-04-14 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development
WO2021127017A1 (en) * 2019-12-16 2021-06-24 La Jolla Institute For Immunology Combinations of flavivirus proteins, peptide sequences, epitopes, and methods and uses thereof
CN117157524A (zh) * 2020-10-07 2023-12-01 赛诺菲巴斯德有限公司 改良的诊断测试
WO2022162009A1 (en) 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies
WO2022161597A1 (en) * 2021-01-26 2022-08-04 Eth Zurich Method for rapid identification of cross-reactive and/or rare antibodies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
DE3223885A1 (de) 1982-06-26 1983-12-29 Basf Ag, 6700 Ludwigshafen Makroporoese, hydrophile traeger fuer enzyme
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
WO1994019376A1 (fr) 1993-02-26 1994-09-01 Drug Delivery System Institute, Ltd. Derive de polysaccharide et vehicule de medicament
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
ATE277640T1 (de) 1994-03-07 2004-10-15 Dow Chemical Co Bioaktive und/oder gezielte dendrimere-konjugate enthaltend genetisches material
US5786387A (en) 1994-03-23 1998-07-28 Meiji Seika Kabushiki Kaisha Lipid double-chain derivative containing polyoxyethylene
JP3699141B2 (ja) 1994-09-24 2005-09-28 伸彦 由井 超分子構造の生体内分解性医薬高分子集合体及びその調製方法
US5490840A (en) 1994-09-26 1996-02-13 General Electric Company Targeted thermal release of drug-polymer conjugates
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6106866A (en) 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
HRP20130077A2 (hr) 1998-12-23 2013-07-31 Pfizer Inc. Humana monoklonalna protutjela za ctla-4
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US7622113B2 (en) * 2003-12-08 2009-11-24 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
TWI445547B (zh) 2007-06-08 2014-07-21 Nat Health Research Institutes 登革熱病毒胜肽疫苗及其製備與使用方法
GB0724065D0 (en) 2007-12-10 2008-01-16 Sparrow Paul A A spirit level
WO2009152147A2 (en) 2008-06-09 2009-12-17 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination
CN102272155B (zh) 2008-10-13 2018-05-25 生物医学研究所 登革热病毒中和抗体及其用途
SG173482A1 (en) 2009-02-10 2011-09-29 Univ Nanyang Tech Antibodies for diagnosis and treatment of flaviviral infections
ES2644236T3 (es) 2010-12-14 2017-11-28 National University Of Singapore Anticuerpo humano monoclonal con especificidad para el virus Dengue serotipo 1 E proteína y usos de la misma

Also Published As

Publication number Publication date
EP2651975A4 (en) 2014-05-21
EP2651975A1 (en) 2013-10-23
MX348152B (es) 2017-06-02
SG10201510111PA (en) 2016-01-28
PH12017501075A1 (en) 2018-02-12
KR101781546B1 (ko) 2017-09-26
CO6801636A2 (es) 2013-11-29
JP2014502839A (ja) 2014-02-06
CA2821268A1 (en) 2012-06-21
ES2644236T3 (es) 2017-11-28
EA201390874A1 (ru) 2013-12-30
RS56737B1 (sr) 2018-03-30
MX2013006710A (es) 2014-09-25
US9376486B2 (en) 2016-06-28
US10294293B2 (en) 2019-05-21
WO2012082073A1 (en) 2012-06-21
EP2651975B1 (en) 2017-08-09
JP6483337B2 (ja) 2019-03-13
LT2651975T (lt) 2018-02-12
PH12013501242B1 (en) 2019-01-30
HUE035609T2 (hu) 2018-05-28
AU2011341744B2 (en) 2016-09-08
MY201732A (en) 2024-03-14
PT2651975T (pt) 2017-11-14
MY166537A (en) 2018-07-10
BR112013015129A2 (en) 2018-10-09
US20130259871A1 (en) 2013-10-03
PH12017501075B1 (en) 2019-11-29
SI2651975T1 (en) 2018-03-30
CA2821268C (en) 2021-06-15
PH12013501242A1 (en) 2013-08-12
BR112013015129B1 (pt) 2022-11-16
AU2016269515A1 (en) 2017-01-05
HRP20171580T1 (hr) 2018-01-26
IL226957B (en) 2020-03-31
AU2011341744A1 (en) 2013-07-18
KR20170110159A (ko) 2017-10-10
CN103534270B (zh) 2017-03-08
JP2018046835A (ja) 2018-03-29
DK2651975T3 (en) 2017-10-30
US20170029489A1 (en) 2017-02-02
ZA201304459B (en) 2019-11-27
CY1119854T1 (el) 2018-06-27
KR101904232B1 (ko) 2018-10-05
SMT201700477T1 (it) 2018-01-11
SG191155A1 (en) 2013-07-31
KR20140019777A (ko) 2014-02-17
CN103534270A (zh) 2014-01-22

Similar Documents

Publication Publication Date Title
IL285226B (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
IL272831A (en) Meditopes and meditope-binding antibodies and uses thereof
IL262073B (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
PT2651975T (pt) Anticorpo monoclonal humano com especificidade para a proteína do vírus do dengue de seroptipo 1 e suas utilizações
HRP20170983T1 (hr) Pripravci s visokom koncentracijom antitijela
IL244801B (en) Human il-23 antigen binding proteins
IL254004A0 (en) Monoclonal antibodies to progastrin and their uses
IL222507B (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
HRP20181811T1 (hr) Zbirka sljedova protutijela i njezina upotreba
PT2424896E (pt) Anticorpos anti-ceacam1 e métodos de utilização dos mesmos
HUE053720T2 (hu) ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
EP2408921A4 (en) MODIFICATION OF CXCR4 USING MODIFIED ZINC FINGER PROTEINS
BR112015003838A2 (pt) formulações de anticorpo e proteína
IL237828B (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
CO7020851A2 (es) Proteínas y péptidos modificados
HUE043355T2 (hu) LIV-1 elleni humanizált antitestek és alkalmazásuk a rák kezelésében
HUE057004T2 (hu) CD277 elleni antitestek és alkalmazásaik
PT2580240T (pt) Anticorpos as100a4 e utilizações terapêuticas dos mesmos
IL226427A0 (en) Anti ccr4 antibodies and uses thereof
IL225389A0 (en) Antibody compositions and methods of use
PL2776460T3 (pl) Białko fuzyjne zawierające interleukinę 4 i interleukinę 10
HRP20181973T1 (hr) Poboljšana anti humana fraktalkinska protutijela i njihova uporaba
BR112015003032A2 (pt) anticorpos anti-jagged e métodos de utilização'.
IL223665B (en) Human antibodies to human cytomegalovirus (cmv) gb protein
EP2650367A4 (en) HUMAN MONOCLONAL ANTIBODY